US Biosimilars: 40% First-Cycle Approval Rate Leaves Room For Improvement
Executive Summary
Four of first 10 publicly disclosed applications were approved on first review cycle, and FDA has issued at least seven complete response letters. Increasing first-cycle approvals is a primary goal of the BsUFA II agreement.
You may also be interested in...
US FDA's Biosimilars Program: Five Years In, Complete Response Letters Still Outnumber Approvals
Agency is meeting its review timelines for biosimilar applications but handing our more complete response letters than first-cycle approvals; sponsors have publicly disclosed 24 original biosimilar application submissions to the agency since the review program began in fiscal year 2013, with 10 product approvals to date and at least 13 CRLs, according to the Pink Sheet's biosimilars report card.
US FDA's Biosimilars Program: Five Years In, Complete Response Letters Still Outnumber Approvals
Agency is meeting its review timelines for biosimilar applications but handing our more complete response letters than first-cycle approvals; sponsors have publicly disclosed 24 original biosimilar application submissions to the agency since the review program began in fiscal year 2013, with 10 product approvals to date and at least 13 CRLs, according to the Pink Sheet's biosimilars report card.
Biosimilar User Fees Discounted To Begin Second Round
After adjusting for expected workload, US FDA reduces biosimilar user fee revenue target, which lowered application fees.